Organization
San Francisco Department of Public Health
1 clinical trial
13 abstracts
Clinical trial
Phase 1 Safety-interaction Study of Mirtazapine for the Treatment of Methamphetamine Use DisorderStatus: Recruiting, Estimated PCD: 2025-12-31
Abstract
Patient-derived skin MicroOrganoSpheres and clinical response to immunotherapy.Org: Xilis, Durham Veteran Affairs Medical Center, NC Medical Research, Xilis Inc, Xilis, Inc.,
Abstract
MRD assay to evaluate recurrence and response via a tumor-informed assessment: MARIA-Breast observational trial.Org: Invitae, San Francisco Department of Public Health, CanSino Biologics, Iselin, NJ,
Abstract
Surgical care and outcomes in older patients with cancer through implementation of a pre-surgical toolkit (OPTI-Surg): Interim results of a phase III cluster randomized trial (Alliance A231601CD).Org: MD Anderson Cancer Center, Alliance Statistics and Data Management Center, Mayo Clinic, American College of Surgeons, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: A surrogate of pelvic lymph node dissection? Follow-up analysis of a multicenter prospective phase 3 imaging trial.Org: UCLA Ahmanson Translational Theranostics Division, Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, UCLA Nuclear Medicine, Department of Radiology and Biomedical Imaging, University of California Irvine,
Abstract
Biomarkers of response to sacituzumab govitecan (SG) and efficacy after treatment with enfortumab vedotin (EV) in advanced urothelial carcinoma (aUC): Analysis of the UNITE study.Org: University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, MD Anderson Hematology/Oncology Fellowship, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Washington and Fred Hutchinson Cancer Research Centre,
Abstract
Phase II study of niraparib in patients with advanced melanoma with genetic homologous recombination (HR) mutation/alteration.Org: California Pacific Medical Center Research Institute, San Francisco, CA, San Francisco Department of Public Health,
Abstract
Sequential learning for pan-tumor detection of metastatic disease progression.Org: Syapse, San Francisco Department of Public Health, CanSino Biologics,
Abstract
Outcomes of patients with advanced NF1-mutant melanoma treated with MEK inhibitors.Org: California Pacific Medical Center Research Institute, San Francisco, CA, San Francisco Department of Public Health, CanSino Biologics, Stockton Hematology/Oncology, Lodi,
Abstract
Cure-PROs: Next-generation targeted protein degraders.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC, MRP Pharma LLC, Chapel Hill, NC, Consultant,
Abstract
Real-world evidence study of treatment patterns and outcomes following covalent BTKi discontinuation in a contemporary cohort of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients.Org: Dana-Farber Cancer Institute, Boston Pharmaceuticals, MaaT Pharma, Analysis Group, Inc., Inc.,
Abstract
ARE PATIENT RATINGS OF PROVIDERS AND HEALTH PLANS ASSOCIATED WITH TECHNICAL QUALITY OF CARE IN SLE? Org: Medicine, Kuopio University Hospital, Kuopio, UCSF Helen Diller Family Comp Cancer Ctr, San Francisco Department of Public Health, United States Army Research Institute of Environmental Medicine,
Abstract
ABILITY OF MEASURES OF FUNCTION AND INFLAMMATION TO PREDICT LONG-TERM PATIENT-REPORTED DISEASE IMPACT AND DISABILITY IN RAOrg: Medicine and Frontier Science Center of Disease Molecular Network, University of California Irvine, San Francisco Department of Public Health, GHEOR, Amgen,
Abstract
ASSESSING THE IMPACT OF ETANERCEPT TREATMENT ON PRODUCTIVITY: RESULTS FROM A RECENT RA PATIENT WORK LOSS AND PRODUCTIVITY SURVEYOrg: McKesson Specialty Health, McKesson Corporation, San Francisco Department of Public Health, Global Health Economics and Pricing, Amgen, Inc., Deerfield, United States of America,